Nitsche D, Tschurtschenthaler G, Stöger M, Michlmayr G
Dtsch Med Wochenschr. 1985 Dec 13;110(50):1936-9. doi: 10.1055/s-2008-1069116.
Nine patients with blast crises of chronic myeloid leukaemia were treated with a combination of vindesine and prednisolone. Vindesine, 2 mg/m2, was administered intravenously on two successive days each week and prednisolone, 60 mg/m2, orally once daily. Blast crises were divided into myeloblastic and lymphoblastic ones using cytochemical parameters as well as detection of terminal deoxynucleotidyl transferase. Complete remission was achieved in four patients, partial remission in one patient; in four patients treatment was unsuccessful. According to cytochemical findings, a therapeutic success was obtained in three of four patients with lymphoblastic and two of four patients with myeloblastic crises whereas no response to the treatment was seen in one patient with an undifferentiated type. Side effects of the therapy were frequent, but of only low degree and never led to interruption of treatment. On the basis of these results and from experience reported in the literature, the combination of vindesine and prednisolone can be recommended as the therapy of choice in blast crises of chronic myeloid leukaemia.
9例慢性髓性白血病急变期患者接受了长春地辛与泼尼松龙联合治疗。长春地辛剂量为2mg/m²，每周连续2天静脉给药；泼尼松龙剂量为60mg/m²，每日口服1次。根据细胞化学参数以及末端脱氧核苷酸转移酶检测结果，将急变期分为髓母细胞型和淋巴细胞母细胞型。4例患者达到完全缓解，1例患者部分缓解；4例患者治疗未成功。根据细胞化学检查结果，淋巴细胞母细胞型4例患者中有3例治疗成功，髓母细胞型4例患者中有2例治疗成功，而1例未分化型患者对治疗无反应。治疗的副作用很常见，但程度较轻，从未导致治疗中断。基于这些结果以及文献报道的经验，长春地辛与泼尼松龙联合治疗可推荐为慢性髓性白血病急变期的首选治疗方法。
